Inclusion Criteria:

          -  Age ≥ 18 years

          -  Must meet criteria for high-risk MGUS or low-risk smoldering myeloma as described
             below:

        High-Risk MGUS

        Must have <10% plasma cells and <3.0g/dL M-spike and at least 2 of the following 3
        criteria:

          -  Abnormal free light-chain (FLC) ratio (<0.26 or >1.65)

          -  M-protein concentration (≥1.5 g/dL)

          -  Non-IgG M protein (including IgA)

        Low-Risk Smoldering Multiple Myeloma

        Must only present with 1 of the following criterion:

          -  Monoclonal Protein ≥ 3 g/dL

             ---≥ 10% Bone Marrow Plasma Cells

          -  FLC ratio < 0.125 or > 8

             -No evidence of CRAB criteria† or new criteria of active MM which including the
             following:

               -  Increased calcium levels (corrected serum calcium >0.25 mmol/dL above the upper
                  limit of normal or >0.275 mmol/dL)

               -  Renal insufficiency (attributable to myeloma)

               -  Anemia (Hb 2 g/dL below the lower limit of normal or <10 g/dL)

               -  Bone lesions (lytic lesions or generalized osteoporosis with compression
                  fractures)

               -  No evidence of the following new criteria for active MM including the following:
                  Bone marrow plasma cells >60%, Serum involved/uninvolved FLC ratio ≥100, and MRI
                  with more than one focal lesion

                    -  Participants with CRAB criteria that are attributable to conditions other
                       than the disease under study may be eligible

                    -  ECOG Performance Status (PS) 0, 1, or 2 (Appendix A)

                    -  The following laboratory values obtained ≤ 21 days prior to registration:

               -  ANC ≥ 1000/uL

               -  PLT ≥ 50,000/uL

               -  Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal
                  patient is eligible.)

               -  AST ≤ 3 x institutional upper limit of normal (ULN)

               -  ALT ≤ 3 x institutional upper limit of normal (ULN)

               -  Creatinine ≤ 2 mg/dL or Creatinine Clearance ≥ 40 mL/min

                    -  Ability to understand and the willingness to sign an informed consent before
                       performance of any study-related procedure not part of normal medical care,
                       with the understanding that consent may be withdrawn by the subject at any
                       time without prejudice to future medical care.

                    -  Female patients who are postmenopausal for at least 1 year before the
                       screening visit or are surgically sterile are eligible. Females of
                       childbearing potential (as defined below) may also be eligible but must have
                       a negative serum or urine pregnancy test with a sensitivity of at least 25
                       mIU/mL within 21 days of registration.

               -  A female of childbearing potential is a sexually mature female who:

          -  Has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral
             oophorectomy (the surgical removal of both ovaries)

        OR

        ---Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule
        out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any
        time during the preceding 24 consecutive months)

        Exclusion Criteria:

          -  Any prior therapy for symptomatic Multiple Myeloma or smoldering Multiple Myeloma
             should also be excluded, including prior use of IMIDs, proteasome inhibitors, or CD138
             inhibitors. Prior therapy for smoldering Multiple Myeloma with agents that are not
             therapeutically active against MM is not an exclusion criterion.

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational. Prior therapy with bisphosphonates is allowed. Prior
             radiation therapy to a solitary plasmacytoma is allowed.

          -  Concurrent exposure to any commercially available agents known to be active against
             SMM and MM.

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.

          -  Subject has known chronic obstructive pulmonary disease (COPD) with a Forced
             Expiratory Volume in 1 second (FEV1) < 50% of predicted normal.

          -  Note that FEV1 testing is required for patients suspected of having COPD and subjects
             must be excluded if FEV1 <50% of predicted normal.

               -  Subject has known moderate or severe persistent asthma within the past 2 years or
                  currently has uncontrolled asthma of any classification.

               -  Subjects who currently have controlled intermittent asthma or controlled mild
                  persistent asthma are allowed in the study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris,
             uncontrollable cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Pregnant or nursing women will be excluded from the study.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Daratumumab.

          -  Known seropositive for or active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are
             seropositive because of hepatitis B virus vaccine are eligible. Patients who are
             positive for hepatitis B core antibody or hepatitis B surface antigen must have a
             negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR
             positive will be excluded.

          -  Major surgery within 4 weeks before enrollment.

          -  Subject is known or suspected of not being able to comply with the study protocol (eg,
             because of alcoholism, drug dependency, or psychological disorder). Subject has any
             condition for which, in the opinion of the investigator, participation would not be in
             the best interest of the subject (eg, compromise the well-being) or that could
             prevent, limit, or confound the protocol-specified assessments.

          -  Vaccination with live attenuated vaccines within 4 weeks of first study agent
             administration

          -  Subject has clinically significant cardiac disease, including significant ischemic
             coronary disease, congestive heart failure (New York Heart Association [NYHA] Class
             III or IV), unstable arrhythmias, myocardial infarction or unstable angina within 6
             months before randomization, a history of additional risk factors for torsades de
             pointes (eg, electrolyte abnormalities, family history of Long QT Syndrome), or a
             family history of sudden cardiac death before age 40.

          -  Participation in other therapeutic clinical trials, including those with other
             investigational agents not included in this trial, within 30 days of the start of this
             trial and throughout the duration of this trial